Selank + Semax Blend 20mg Exclusive Royal custom Blend🔥Match available documentation to the applicable research material and batch.
Royal Peptides products are offered exclusively for laboratory research, analytical, and scientific applications. Not for human or veterinary use.
Royal Peptides supplies compounds intended for controlled laboratory research and analytical applications.
Where applicable, Royal Peptides research materials are supplied in lyophilized form.
Lyophilization is a freeze-drying process used to remove moisture from material under controlled conditions.
Storage requirements may vary by compound, formulation, and production lot. Refer to the product label and available product-specific documentation.
Packaging components may vary slightly between production lots. This can include vial closures, cap styles, label positioning, and external packaging.
A defined dual-component research formulation containing Selank 10 mg and Semax 10 mg in a single 20 mg lyophilized research vial. The formulation combines two distinct synthetic heptapeptides for controlled multi-component peptide research.
Not for human or veterinary use, administration, ingestion, injection, compounding, diagnostic, therapeutic, clinical, or personal use.
The Selank + Semax 20 mg blend is a defined two-component research formulation containing equal quantities of two structurally distinct synthetic heptapeptides.
Selank is structurally related to the tuftsin peptide sequence, while Semax is structurally associated with an ACTH-derived peptide fragment. Both contain seven amino-acid residues but maintain separate molecular identities within the blend.
Royal Peptides supplies this formulation exclusively as a laboratory research material for controlled analytical and experimental investigation.
The 20 mg vial contains a defined 1:1 composition by labeled peptide mass, providing equal quantities of Selank and Semax within a single research formulation.
Synthetic heptapeptide structurally derived from a tuftsin-related peptide sequence.
Synthetic heptapeptide structurally associated with an ACTH-derived peptide fragment.
Selank provides one defined seven-residue peptide sequence within the formulation and retains its individual compound identity for analytical research.
Semax provides a separate seven-residue peptide sequence within the formulation and remains analytically distinct from Selank.
Both peptide sequences contain a Pro-Gly-Pro sequence at their C-terminal region, providing a useful structural feature for comparative laboratory investigation.
Equal labeled quantities provide a controlled dual-component material for experiments requiring a predefined Selank-to-Semax ratio.
Selank and Semax have individually appeared in experimental literature involving peptide-associated molecular and neurobiological systems. A blended material can support controlled research designs where both defined peptide components are evaluated within the same experimental system.
Researchers may investigate structural or analytical similarities and differences between the two defined heptapeptide components.
Controlled experimental systems may examine measurable molecular variables associated with peptide signaling pathways.
The formulation provides a defined dual-component material for analytical methods designed to distinguish or quantify multiple peptide constituents.
The distinct parent sequences together with their shared Pro-Gly-Pro terminal motif provide structural variables for controlled comparative investigation.
Laboratory evaluation should rely on analytical documentation corresponding to the specific production lot received. For a multi-component formulation, researchers should distinguish between total labeled material quantity and the identity or measured content of each individual peptide component.
Appropriate research records should connect experimental observations to the specific Selank + Semax production lot incorporated into the laboratory workflow.
Record the formulation name, individual component quantities, total labeled quantity, production lot, date received, and applicable internal laboratory identifier.
Preserve applicable analytical documentation, experimental observations, results, material-control records, and other records associated with the specific research lot.
Selank + Semax research material should be handled using appropriate laboratory procedures intended to preserve material identity, minimize contamination, and maintain experimental traceability.
Maintain clear identification of the dual-component material throughout receipt, storage, analytical preparation, and experimental workflows.
Follow storage information associated with the applicable product label and batch documentation rather than relying on generalized storage claims.
Royal Peptides Selank + Semax 20 mg is supplied exclusively as a laboratory research material. It is not offered or represented as a medicine, pharmaceutical preparation, dietary supplement, food, cosmetic, or consumer health product.
The formulation contains 10 mg of Selank and 10 mg of Semax, providing 20 mg total labeled peptide material in a 1:1 ratio.
No. It is a blend containing two separate synthetic heptapeptides. Selank and Semax retain distinct amino-acid sequences and molecular identities.
Selank is commonly identified as Thr-Lys-Pro-Arg-Pro-Gly-Pro, abbreviated TKPRPGP.
Semax is commonly identified as Met-Glu-His-Phe-Pro-Gly-Pro, abbreviated MEHFPGP.
Selank is structurally related to a tuftsin-derived peptide sequence, while Semax is associated with an ACTH-derived peptide fragment. They are distinct compounds despite both being seven-residue peptides.
Both are synthetic heptapeptides and both contain a Pro-Gly-Pro sequence at their C-terminal region. Their remaining sequences and structural origins differ.
No. Royal Peptides supplies this formulation strictly for laboratory research. It is not intended for human or veterinary administration.
No. Royal Peptides does not provide dosing, administration, injection, prescribing, treatment, or personal-use instructions for this research material.
Batch-specific analytical documentation may be available for the applicable production lot. Researchers should review documentation corresponding to the specific material received.
Selank + Semax 20 mg is supplied for laboratory research use only. Not for human or veterinary use. Not intended for administration, ingestion, injection, personal experimentation, pharmaceutical compounding, pharmacy preparation, diagnostic use, therapeutic use, or clinical use. Nothing on this page constitutes medical advice or represents this research material as intended to diagnose, treat, cure, mitigate, or prevent any disease or medical condition.
Product information pulled directly from WooCommerce.
Review available analytical documentation for the applicable product and batch.
View Analytical Documentation →Match available documentation to the applicable research material and batch.
Review the analytical information provided for the selected batch where available.
Keep relevant product and batch documentation with your research records.
Shipping options and delivery estimates are shown at checkout. Refer to the product label and applicable documentation for handling and storage information.
Complete payment using the available methods presented during checkout.
Tracking information is provided when available for the selected delivery service.
Use the product label and applicable documentation for handling and storage guidance.
Selank + Semax Blend 20mg Exclusive Royal custom Blend🔥
Selank + Semax Blend 20mg Exclusive Royal custom Blend🔥
PREMIUM RESEARCH MATERIALS
You must be at least 21 years old to enter. All products are intended strictly for laboratory research only — not for human or veterinary use or consumption.
INDEPENDENT RESEARCH • QUALITY • TRANSPARENCY
Verification remembered for 30 days